Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

797
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
797
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

2.9K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
2.9K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

973
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
973
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.1K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.1K
Competition02:34

Competition

24.8K
When organisms require the same limited resources within an environment, they may have to compete for them. Competition is a net-negative interaction. Even if two competing individuals or populations do not interact directly, the overall fitness of both competitors is lowered as a result of not having full access to the limited resource.
24.8K
Regulation of Sodium and Potassium01:26

Regulation of Sodium and Potassium

2.3K
The regulation of sodium and potassium ion concentrations in the human body is a complex process governed primarily by hormones such as aldosterone, antidiuretic hormone (ADH), and atrial natriuretic peptide (ANP).
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CLEIA-based type IV collagen 7S for second-step assessment of MRE-defined clinically significant fibrosis in MASLD with indeterminate FIB-4.

Scientific reports·2026
Same author

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report.

Frontiers in immunology·2026
Same author

Gastric metastasis from pancreatic ductal adenocarcinoma: a case report.

Journal of surgical case reports·2026
Same author

The usefulness of the novel 0.018-inch dedicated uneven double-lumen cannula for endoscopic ultrasound-guided hepaticogastrostomy using a 22-gauge needle.

Endoscopy·2026
Same author

Case report: Epidermolysis bullosa acquisita following dipeptidyl peptidase-4 inhibitor therapy and complicated by immune thrombocytopenic purpura.

Frontiers in immunology·2026
Same author

Pancreatitis Following Biliary Endoscopic Retrograde Cholangiopancreatography for Common Bile Duct Stones in Japan: A Multicenter Prospective Cohort Study.

DEN open·2025

Related Experiment Video

Updated: Jan 31, 2026

Oligopeptide Competition Assay for Phosphorylation Site Determination
09:16

Oligopeptide Competition Assay for Phosphorylation Site Determination

Published on: May 18, 2017

8.9K

Potassium-competitive acid blocker.

Ken Haruma, Mitsuhiko Suehiro, Hirofumi Kawamoto

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |December 19, 2018
    PubMed
    Summary

    Vonoprazan, a novel potassium-competitive acid blocker, shows superior efficacy in healing severe reflux esophagitis (RE) compared to proton pump inhibitors (PPIs). Long-term safety data for Vonoprazan are still needed.

    Area of Science:

    • Gastroenterology
    • Pharmacology

    Background:

    • Proton pump inhibitors (PPIs) are first-line for reflux esophagitis (RE), but treatment failure occurs in up to 30% of severe cases.
    • Factors like PPI metabolism, enzyme polymorphism, H. pylori infection, and hernia affect PPI effectiveness.

    Purpose of the Study:

    • To evaluate the efficacy of Vonoprazan, a potassium-competitive acid blocker (P-CAB), for severe RE.
    • To compare Vonoprazan's acid-suppressing capabilities with existing PPIs.

    Main Methods:

    • Clinical study comparing Vonoprazan and PPIs in patients with severe RE.
    • Assessment of gastric acidity control, including daytime and nighttime, and healing rates.

    Main Results:

    • Vonoprazan achieved adequate gastric acid control, including overnight, from day 1 of administration.

    More Related Videos

    Metal-free Synthesis of Ynones from Acyl Chlorides and Potassium Alkynyltrifluoroborate Salts
    09:58

    Metal-free Synthesis of Ynones from Acyl Chlorides and Potassium Alkynyltrifluoroborate Salts

    Published on: February 24, 2015

    11.7K
    Comparing the Affinity of GTPase-binding Proteins using Competition Assays
    10:37

    Comparing the Affinity of GTPase-binding Proteins using Competition Assays

    Published on: October 8, 2015

    9.6K

    Related Experiment Videos

    Last Updated: Jan 31, 2026

    Oligopeptide Competition Assay for Phosphorylation Site Determination
    09:16

    Oligopeptide Competition Assay for Phosphorylation Site Determination

    Published on: May 18, 2017

    8.9K
    Metal-free Synthesis of Ynones from Acyl Chlorides and Potassium Alkynyltrifluoroborate Salts
    09:58

    Metal-free Synthesis of Ynones from Acyl Chlorides and Potassium Alkynyltrifluoroborate Salts

    Published on: February 24, 2015

    11.7K
    Comparing the Affinity of GTPase-binding Proteins using Competition Assays
    10:37

    Comparing the Affinity of GTPase-binding Proteins using Competition Assays

    Published on: October 8, 2015

    9.6K
  • Vonoprazan demonstrated superior effectiveness in healing severe RE compared to current PPIs.

    • Conclusions:

    • Vonoprazan offers a more effective treatment option for severe reflux esophagitis than traditional PPIs.
    • Further long-term studies are necessary to assess potential adverse events like hypergastrinemia associated with Vonoprazan.